Efficacy of Rabeprazole in the Treatment of Symptomatic Gastroesophageal Reflux Disease
- 178 Downloads
The purpose of this study was to assess the rapidity of symptom relief and 4-week efficacy of rabeprazole 20 mg in patients with moderately severe nonerosive gastroesophageal reflux disease. Data were analyzed from 2 similarly designed, double-blind, placebo-controlled, multicenter, U.S. trials. After a 2-week placebo run-in period, patients (N = 261) were randomized to 4 weeks of rabeprazole 20 mg once daily or placebo. Patients kept symptom diaries and scored symptom severity. Median time to first 24-hour heartburn-free interval was 3.5 days for the rabeprazole group compared with 19.5 days for the placebo group (P ≤ .0002). Complete heartburn relief at week 4 was 32% with rabeprazole and 3.8% with placebo (P ≤ .001). Rabeprazole also significantly improved other GERD-associated symptoms (e.g., regurgitation, belching, early satiety) by week 4 compared with placebo (P ≤ .05). Rabeprazole provides fast and potent relief from heartburn and other symptoms of nonerosive gastroesophageal reflux disease.
Keywordsgastroesophageal reflux disease symptoms nonerosive gastroesophageal reflux disease proton pump inhibitor rabeprazole
Unable to display preview. Download preview PDF.
- 1.A Gallup Organization National Survey: Heartburn across America. Princeton, NJ, Gallup Organization, 1988Google Scholar
- 6.Smout AJ: Endoscopy-negative acid reflux disease. Aliment Pharmacol Ther 22:81–85, 1997Google Scholar
- 16.Williams MP, Sercombe J, Hamilton MI, Pounder RE: A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment Pharmacol Ther 12:1079–1089, 1998CrossRefPubMedGoogle Scholar
- 17.Cloud ML, Enas N, Humphries TJ, Bassion S: Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group. Dig Dis Sci 43:993–1000, 1998CrossRefPubMedGoogle Scholar
- 18.Dekkers CP, Beker JA, Thjodleifsson B, Gabryelewicz A, Bell NE, Humphries TJ: Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther 13:49–57, 1999PubMedGoogle Scholar
- 19.Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ: Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci 45:845–853, 2000CrossRefPubMedGoogle Scholar
- 27.Sanders SW: Pathogenesis and treatment of acid peptic disorders: comparison of proton pump inhibitors with other antiulcer agents. Clin Ther 18:2–34, 31, 1996Google Scholar
- 28.Bruley des Varannes S, Galmiche JP: Evaluation of Esophageal Sensitivity, vol. 22. Basel, Karger, 1994Google Scholar
- 29.Pehlivanov N, Liu J, Mittal R: Sustained esophageal contraction: a motor correlate of heartburn symptom [abstract # G4613]. Gastroenterology 116:1999Google Scholar